The UK and US have forged a major trade agreement that will guarantee no tariffs on UK pharmaceutical shipments entering the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This pledge secures that import taxes on these vital exports will remain at nothing for a duration of 36 months.
This deal is in response to recent warnings to significantly raise tariffs on branded drug imports, with potential rates mentioned as high as double the cost.
"This deal between the UK strengthens the international landscape for cutting-edge drugs and brings long-overdue fairness to American-British medicine commerce," a release noted.
Commercial Importance
Pharmaceuticals are one of the UK's most significant goods shipped to the America, which is by far the biggest destination for major UK drugmakers.
Export figures indicate that in the year leading up to September, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This figure represented a significant portion of British export trade in that span.
"This guarantee safeguards employment, boosts capital expenditure and facilitates the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The pact includes several key pledges from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to double overall health service expenditure on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The sum manufacturers must pay back to the NHS to stay within budget will be restricted at 15%. Previously, rebates were more than 20%.
Recent Tensions
The pact comes amid a long-running tension between the sector and the UK government over spending levels and NHS adoption.
The disagreement were exacerbated by assertions that American customers were paying a premium for the equivalent treatments than people in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar expansions have been pledged toward projects in the United States.
One official acknowledged that the NHS had to invest a greater share on treatments, noting that its spending on drugs had decreased as a percentage of its total funding over the last ten years.
